Soleno Therapeutics, Inc.
SLNO
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program. The company waā¦ read more
Healthcare
Biotechnology
10 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$47.70
Price+9.56%
$4.16
1Y
Price
Market Cap
$2.562b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-8.7%
EBITDA Margin-14.4%
Net Profit Margin-38.6%
Free Cash Flow MarginRevenue
$32.657m
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$181.079m
-3.0%
1y CAGR-148.6%
3y CAGR-103.7%
5y CAGREPS
-$4.14
+5.5%
1y CAGR-25.9%
3y CAGR-5.3%
5y CAGRBook Value
$240.140m
$332.306m
Assets$92.166m
Liabilities$52.769m
DebtDebt to Assets
15.9%
-0.3x
Debt to EBITDAFree Cash Flow
-$84.490m
-21.9%
1y CAGR-73.2%
3y CAGR-48.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company